San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Bluestar Genomics is raising $71,621,122.00 in new funding. Sources indicate as part of senior management Chief Executive Officer and Chief Scientific Officer, Samuel Levy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bluestar Genomics
Bluestar Genomics is an exciting new startup life science company that is reinventing non-invasive molecular diagnostic testing using next generation epigenomic technologies. We are passionate and dedicated to discovering and developing medicines that will make a significant difference in cancer and other epigenomic-driven diseases. Our technologies provide novel insight and quantitation of human health and disease, with our focus on precision medicine applications improving both clinical and health system outcomes. Our company was founded based on pioneering work in the Stanford laboratory of Stephen Quake, with advisors from Stanford, Oxford, U. Chicago, and UCSF. We are leveraging a world-class network with our founding team which has been previous innovators and leaders within many of the premier nucleic acid, liquid biopsy, and single-cell genomics companies. We are based in San Francisco and San Diego.

To learn more about Bluestar Genomics, visit http://www.bluestargenomics.com/

Contact:
Samuel Levy, Chief Executive Officer and Chief Scientific Officer
833-258-7827
slevy@bluestargenomics.com
https://www.linkedin.com/in/samuel-levy-6ab1021/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved